» Articles » PMID: 24394496

A Novel Community-based Buprenorphine Program: Client Description and Initial Outcomes

Overview
Journal J Addict Med
Specialty Psychiatry
Date 2014 Jan 8
PMID 24394496
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

The aims of this retrospective, descriptive study were to describe clients served by a buprenorphine program in a community-based recovery center and to present initial treatment outcomes. A record review was conducted for clients treated from July 2010 to August 2011. Client demographic, health, substance use, and treatment history data were abstracted from the records of the first 78 clients served. Buprenorphine and opiate use data were collected via urine toxicology reports, collected weekly among clients who remained enrolled in treatment. The average percentages of weeks spent opiate free and buprenorphine compliant were 83% (SD = 26%) and 95% (SD = 13%), respectively. When positive heroin toxicology and negative buprenorphine toxicology were replaced for the missing/unknown data, the average percentages of opiate-abstinent weeks and buprenorphine compliance were 60% (SD = 34%) and 74% (SD = 28%), respectively. Roughly half of all clients (49%) were successfully transitioned to continue treatment with buprenorphine in a primary care setting. Findings from this study demonstrate that buprenorphine treatment for opiate dependence can be incorporated into a community-based recovery center with high rates of opiate abstinence and treatment adherence.

Citing Articles

Characterizing Opioid Withdrawal Experiences and Consequences Among a Community Sample of People Who Use Opioids.

Simpson K, Bolshakova M, Kirkpatrick M, Davis J, Cho J, Barrington-Trimis J Subst Use Misuse. 2024; 59(6):886-894.

PMID: 38287506 PMC: 11062512. DOI: 10.1080/10826084.2024.2306221.


Recent Opioid Use Impedes Range Adaptation in Reinforcement Learning in Human Addiction.

Gueguen M, Anllo H, Bonagura D, Kong J, Hafezi S, Palminteri S Biol Psychiatry. 2023; 95(10):974-984.

PMID: 38101503 PMC: 11065633. DOI: 10.1016/j.biopsych.2023.12.005.


Intersecting substance use treatment and harm reduction services: exploring the characteristics and service needs of a community-based sample of people who use drugs.

Krawczyk N, Allen S, Schneider K, Solomon K, Shah H, Morris M Harm Reduct J. 2022; 19(1):95.

PMID: 36002850 PMC: 9400571. DOI: 10.1186/s12954-022-00676-8.


Onsite buprenorphine inductions at harm reduction agencies to increase treatment engagement and reduce HIV risk: Design and rationale.

Perez-Correa A, Abbas B, Riback L, Ghiroli M, Norton B, Murphy S Contemp Clin Trials. 2022; 114:106674.

PMID: 34990854 PMC: 10123766. DOI: 10.1016/j.cct.2021.106674.


Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap.

Krawczyk N, Buresh M, Gordon M, Blue T, Fingerhood M, Agus D J Subst Abuse Treat. 2019; 103:1-8.

PMID: 31229187 PMC: 6612429. DOI: 10.1016/j.jsat.2019.05.002.